한글목차

주요 하이라이트

• 약물 내성 간질 시장은 질환에 대한 인식이 높아지고 보다 효과적인 치료법이 개발됨에 따라 활성화될 것으로 예측됩니다.
• 주요 약제 내성 간질 관련 기업으로는 LivaNova, Neurona Therapeutics, IAMA Therapeutics 등이 있습니다.

약물 내성 간질 시장 인사이트 및 예측

• 약물 내성 간질(난치성 간질이라고도 함)은 두 가지의 항간질제를 적절히 사용해도 발작이 지속되는 경우 진단됩니다. 간질 환자의 약 1/3에서 발생하며, 표준 약물 치료 후에도 발작이 지속되는 특징이 있습니다.
• 2024년 영국에서 실시된 실제 분석에 따르면 약물 내성 간질의 유병률은 26.6%로 추정됩니다. 또한 약제 내성 간질 환자의 심각한 질병 부담도 부각되었습니다.
• 미국내 약제 내성 간질 환자 증가는 간질 유병률 증가, 진단 기술 향상, 평균 수명 연장, 인식 개선에 기인하는 것으로 추정됩니다. 이러한 요인으로 인해 표준 항경련제에 반응하지 않는 환자가 더 많이 발견되고 있습니다.
• 미주신경자극요법(VNS)은 약물 내성 간질에 대한 FDA 승인을 받았으며, 약물에 의존하지 않는 발작 조절을 제공합니다. 이는 치료 결과를 개선하고 약제 내성 간질 관리 전략을 개별화하며, 작용기전을 개선하고 내약성을 향상시키는 새로운 항간질제에 대한 시급한 요구가 있음을 보여줍니다.
• NRTX-1001을 보유한 Neurona Therapeutics, IAMA-6를 보유한 IAMA Therapeutics 등 주요 약제 내성 간질 치료 기업은 임상적 미충족 수요에 대응하고 유망한 효능을 보이는 혁신적인 치료제를 개발하고 있습니다. 이러한 치료법의 승인은 약제 내성 간질 치료 옵션을 크게 확대하여 시장 성장을 가속하고, 치료 효과의 향상과 보급 확대를 통해 막대한 매출을 창출할 것으로 기대됩니다.
• 현재의 약물 내성 간질 치료는 많은 환자에서 발작 억제 효과가 제한적이어서 효과와 내약성이 개선된 진보된 치료법의 필요성이 대두되고 있습니다. 시장에서는 표준 치료제로는 효과가 불충분한 약물 내성 간질의 지속성 발작에 대응할 수 있는 혁신적인 솔루션에 대한 요구가 계속되고 있습니다.

약물 내성 간질 시장의 성장 요인

• 간질 유병률 증가

세계에서 간질 환자 수가 증가하고 기존 항경련제로 발작 억제를 달성할 수 없는 환자의 비율이 높아지면서 약물 내성 간질 환자가 증가하고 있습니다.

• 높은 미충족 의료 수요

간질 환자의 약 1/3이 표준 치료에 내성을 보임에 따라 혁신적이고 효과적인 치료법에 대한 강력한 수요가 발생하고 있습니다.

• 질병 이해의 진행

약제 내성의 기저에 있는 유전적, 분자적, 신경생물학적 기전에 대한 지식이 깊어짐에 따라 표적화된 정밀의료 기반 치료법 개발이 가능해졌습니다.

• 강력한 임상 개발 파이프라인

제약기업과 생명공학 기업은 신규 항경련제, 유전자치료제, 생물제제, 질병 변형 치료 등에 적극적으로 투자하고 있으며, 향후 시장 전망을 강화하고 있습니다.

• 신경 변조 요법의 보급

미주신경자극요법, 심부뇌자극요법, 반응성 신경자극요법의 사용 확대로 약물 치료에 반응하지 않는 환자의 발작 관리가 개선되고 있습니다.

• 진단 능력 향상

신경 영상학의 발전, 장기 뇌파 모니터링, 전문 간질 센터에 대한 접근성 확대는 약물 내성 사례의 조기 발견 및 관리 개선을 지원하고 있습니다.

• 유리한 규제 지원

희귀질환 치료제 지정, 신속 승인, 연구비 증가로 인해 약제 내성 간질 분야의 혁신과 제품 개발이 가속화되고 있습니다.

• 인지도 향상 및 의료 접근성 확대

임상의와 환자의 인식 개선과 더불어 첨단 의료에 대한 접근성 향상으로 진단율과 치료에 대한 이해도가 향상되고 있습니다.

• 삶의 질에 미치는 영향과 의료비

약물 내성 간질로 인한 신체적, 심리적, 경제적 부담이 커지면서 효과적인 장기 치료 솔루션에 대한 수요가 지속적으로 증가하고 있으며, 시장 성장을 지원하고 있습니다.

이 보고서는 미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본 등 주요 7개국(미국, 독일, 스페인, 이탈리아, 프랑스, 영국, 일본)의 약제내성 간질 시장을 조사 분석했으며, 각국 시장 규모와 예측, 각 치료제 시장 점유율, 현재 치료법, 미충족 수요 등에 대해 조사 분석했습니다.

목차

제1장 주요 인사이트

제2장 약물 저항성 간질의 개요

제3장 약물 저항성 간질에 대한 경쟁 정보 분석

제4장 약물 저항성 간질 : 시장의 개요

제5장 약물 저항성 간질 : 질환의 배경과 개요

제6장 환자 여정

제7장 약물 저항성 간질의 역학과 환자 인구

제8장 약물 저항성 간질의 치료 알고리즘, 현재의 치료, 의료 행위

제9장 약물 저항성 간질 미충족 요구

제10장 약물 저항성 간질 치료의 주요 평가항목

제11장 약물 저항성 간질의 출시 약품

제12장 약물 저항성 간질 새로운 치료법

제13장 약물 저항성 간질 : 주요 7 시장의 분석

제14장 속성 분석

제15장 주요 7 시장 : 시장 전망

제16장 약물 저항성 간질의 액세스와 상환의 개요

제17장 KOL의 견해

제18장 약물 저항성 간질 시장 촉진요인

제19장 약물 저항성 간질 시장의 장벽

제20장 부록

제21장 DelveInsight의 서비스 내용

제22장 면책사항

제23장 DelveInsight 소개

영문목차

Key Highlights:

• The Drug-Resistant Epilepsy Market is expected to strengthen as awareness of the disease increases, and more effective interventions are being developed.
• The leading Drug-Resistant Epilepsy Companies, such as LivaNova, Neurona Therapeutics, IAMA Therapeutics, and others.

Drug-Resistant Epilepsy Market Insights & Forecast

• Drug-Resistant Epilepsy, also referred to as refractory epilepsy, is identified when seizures continue despite the use of two suitable and well-tolerated anti-seizure medications. It occurs in approximately one-third of individuals with epilepsy, highlighting the persistence of seizures even after standard medication trials.
• A 2024 real-world analysis in the UK estimated that the prevalence of Drug-Resistant Epilepsy was 26.6%. It also highlighted a significant disease burden among individuals with Drug-Resistant Epilepsy.
• The rise in Drug-Resistant Epilepsy cases in the US is attributed to increased epilepsy prevalence, improved diagnosis, longer life expectancy, and better awareness. These factors contribute to identifying more patients who fail to respond to standard anti-seizure medications.
• Vagus Nerve Stimulation (VNS) is FDA-approved for Drug-Resistant Epilepsy, offering non-pharmacologic seizure control. This underscores an urgent need for novel antiepileptic drugs with improved mechanisms of action and better tolerability to enhance outcomes and personalize Drug-Resistant Epilepsy management strategies
• The leading Drug-Resistant Epilepsy Companies such as Neurona Therapeutics with NRTX-1001, IAMA Therapeutics with IAMA-6, among others. These innovative treatments target unmet clinical needs and offer promising efficacy. Regulatory approval of such therapies could significantly expand the Drug-Resistant Epilepsy treatment landscape, drive market growth, and generate substantial revenue through improved patient outcomes and broader adoption.
• Current treatments for Drug-Resistant Epilepsy offer limited seizure control in many patients, underscoring the need for advanced therapies with improved efficacy and tolerability. The market continues to seek innovative solutions that can address Drug-Resistant Epilepsy's persistent seizures where standard medications fall short.

Factors contributing to the Growth of the "Drug-Resistant Epilepsy Market

• Rising Prevalence of Epilepsy

The increasing global burden of epilepsy and the high proportion of patients who fail to achieve seizure control with existing anti-seizure medications are expanding the drug-resistant epilepsy patient pool.

• High Unmet Medical Need

Approximately one-third of epilepsy patients develop resistance to standard therapies, driving strong demand for innovative and more effective treatment options.

• Advancements in Disease Understanding

Improved insights into genetic, molecular, and neurobiological mechanisms underlying drug resistance are enabling the development of targeted and precision-based therapies.

• Robust Clinical Pipeline

Pharmaceutical and biotechnology companies are actively investing in novel antiseizure drugs, gene therapies, biologics, and disease-modifying approaches, strengthening the future market outlook.

• Growing Adoption of Neuromodulation Therapies

Increased use of vagus nerve stimulation, deep brain stimulation, and responsive neurostimulation is improving seizure management in patients unresponsive to pharmacological treatments.

• Improved Diagnostic Capabilities

Advances in neuroimaging, long-term EEG monitoring, and access to specialized epilepsy centers are supporting early identification and better management of drug-resistant cases.

• Favorable Regulatory Support

Orphan drug designations, fast-track approvals, and increased research funding are accelerating innovation and product development in the drug-resistant epilepsy space.

• Rising Awareness and Healthcare Access

Greater awareness among clinicians and patients, along with improved access to advanced care, is enhancing diagnosis rates and treatment uptake.

• Impact on Quality of Life and Healthcare Costs

The significant physical, psychological, and economic burden of drug-resistant epilepsy continues to drive the need for effective long-term treatment solutions, supporting market growth.

DelveInsight's comprehensive report titled "Drug-Resistant Epilepsy Market Insights, Epidemiology, and Market Forecast - 2036" offers a detailed analysis of Drug-Resistant Epilepsy. The report presents historical and projected epidemiological data covering diagnosed prevalent cases of epilepsy, diagnosed prevalent cases of Drug-Resistant Epilepsy, type-specific diagnosed prevalent cases of Drug-Resistant Epilepsy and gender-specific diagnosed prevalent cases of Drug-Resistant Epilepsy. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across 7MM: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2022 to 2036.

The Drug-Resistant Epilepsy Treatment Market Report analyzes the existing treatment practices and unmet medical requirements in Drug-Resistant Epilepsy. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Drug-Resistant Epilepsy Understanding

Drug-Resistant Epilepsy, also called intractable or refractory epilepsy, is defined as the failure to achieve long-term seizure control despite appropriate trials of two well-chosen and tolerated antiepileptic medications, whether used individually or together. This condition can result from factors such as poor adherence to therapy, inappropriate drug selection or dosing, or misdiagnosis-like confusing nonepileptic events with true epileptic seizures. Individuals are at higher risk of developing Drug-Resistant Epilepsy if they have early-onset epilepsy, intellectual disabilities, symptomatic causes, or abnormal neurological findings. Epilepsy itself may originate from brain injury, developmental structural anomalies, or genetic factors. A single seizure triggered by events such as high fever or head trauma does not constitute Drug-Resistant Epilepsy, which is diagnosed only after experiencing two or more unprovoked seizures. Seizures are generally categorized into generalized onset, focal onset, and unknown onset types, each with further subtypes. Recognizing these classifications is crucial for accurate diagnosis and effective treatment planning.

Drug-Resistant Epilepsy Diagnosis and Treatment Overview

Drug-Resistant Epilepsy requires a thorough, multi-step approach that starts with a neurological evaluation and brain imaging, including Computed Tomography (CT) or Magnetic Resonance Imaging (MRI), to identify structural issues such as tumors or bleeding. Proper seizure classification is also crucial for accurate diagnosis. Typically diagnosed after two unsuccessful trials of Anti-Epileptic Drugs (AEDs), treatment then shifts toward more specialized strategies.

Management may involve pharmacotherapy, often using Sodium Channel Modulators or Synaptic Vesicle Glycoprotein 2A (SV2a) inhibitors, although adding further AEDs has limited effectiveness. Surgical options can be considered for patients with well-defined seizure foci. Complementary approaches-such as neurostimulation, ketogenic diets, and lifestyle changes-can provide additional support. Standard agents like phenytoin and carbamazepine remain commonly used: phenytoin works by modulating sodium channels after depolarization, while carbamazepine's carbamyl group is key to its anticonvulsant action. A personalized, multidisciplinary strategy is essential to achieve the best outcomes in patients with Drug-Resistant Epilepsy.

Drug-Resistant Epilepsy Epidemiology

The epidemiology section of the Drug-Resistant Epilepsy market report offers information on the patient populations, including historical and projected trends for each of the 7MM. Examining Key Opinion Leader (KOL) views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report. This section also presents the data with relevant tables and graphs, offering a clear and concise view of the prevalence of Drug-Resistant Epilepsy. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key findings from the Drug- Resistant Epilepsy Epidemiological Analysis

• According to the secondary analysis, Drug-Resistant Epilepsy affects approximately one-third of the epilepsy patients in the 7MM. Several factors were linked to a higher likelihood of developing Drug-Resistant Epilepsy, such as an early age of seizure onset, epilepsy caused by an identifiable structural or metabolic cause (symptomatic epilepsy), abnormal findings on brain scans or EEG tests, intellectual disability, neuropsychiatric conditions, a history of febrile seizures, and episodes of status epilepticus.
• A retrospective cohort study reported that the prevalence of focal Drug-Resistant Epilepsy ranged from 8.8% in Italy and 18.2% in Germany.
• A US study found that during a one-year follow-up, women were 27% more likely than men to develop treatment-resistant epilepsy, regardless of age.

Drug-Resistant Epilepsy Epidemiology Segmentation in the 7MM

• Diagnosed Prevalent Cases of Epilepsy
• Diagnosed Prevalent Cases
• Type-specific Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases

Drug-Resistant Epilepsy Market Outlook

The Drug-Resistant Epilepsy therapeutics market is further expected to increase by the major drivers, such as the rising prevalent population, technological advancements, and upcoming therapies in the forecast period (2026-2036). Drug-Resistant Epilepsy presents ongoing therapeutic challenges, impacting nearly one-third of individuals with epilepsy. While no drug based therapies are specifically approved for Drug-Resistant Epilepsy, several antiseizure medications-such as clobazam, perampanel, cenobamate, and the recently introduced XEN1101-are used in cases where conventional options fail. For individuals unresponsive to these treatments, alternatives include off-label use of agents like felbamate and vigabatrin, dietary approaches such as the ketogenic diet, and neuromodulation techniques like VNS and responsive neurostimulation (RNS). Surgical resection may be considered for focal epilepsy. Continued development of more targeted and well-tolerated options remains a key focus of current research.

With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Drug-Resistant Epilepsy market in the 7MM is expected to change significantly during the forecast period (2026-2036).

Drug-Resistant Epilepsy Drug Analysis

Drug-Resistant Epilepsy Marketed Drugs

• Vagus Nerve Stimulation (VNS) Therapy: LivaNova

VNS Therapy, created by LivaNova, is a well-established neuromodulation approach aimed at patients with Drug-Resistant Epilepsy, especially those who suffer from partial or generalized seizures and are unsuitable for resective brain surgery.

• In June 2025, LivaNova took a strategic step by beginning the formal process with the US Centers for Medicare and Medicaid Services (CMS) to revisit and potentially expand Medicare coverage of its VNS Therapy-this time aiming to include individuals with unipolar treatment-resistant depression.
• In June 2017, the US FDA expanded approval of VNS Therapy to include Drug-Resistant Epilepsyn as young as four with partial-onset seizures unresponsive to medication-making it the first and only device approved for pediatric Drug-Resistant Epilepsy. Prior to this, it was only approved for patients aged 12 and older.

Drug-Resistant Epilepsy Emerging Drugs

• NRTX-1001: Neurona Therapeutics

NRTX-1001 originates from human stem cells that have been modified to become interneurons, akin to those naturally present in the brain. These cells produce GAMMA-AMINOBUTYRIC ACID (GABA), a crucial neurotransmitter thought to reduce seizure activity by dampening overactive neural signaling.

• In June 2025, Neurona Therapeutics reported that it had dosed the first patient in its Phase I/II clinical trial evaluating NRTX-1001, a regenerative cell therapy, in adults with drug-resistant, bilateral mesial temporal lobe epilepsy (MTLE).
• In April 2025, Neurona Therapeutics shared fresh results from their early-stage clinical trial of NRTX-1001, an experimental treatment for adults with drug-resistant MLTE. The data was presented at this year's American Academy of Neurology, offering a glimpse into potential progress for patients with limited treatment options.
• IAMA-6: IAMA Therapeutics

IAMA-6 is an orally administered small-molecule therapeutic that specifically targets NKCC1 to normalize neuronal excitability. Since increased NKCC1 activity is linked to multiple pathological conditions, inhibiting this transporter holds considerable promise for treating refractory epilepsy and other neurological disorders.

• The company has successfully completed a first-in-human Phase I clinical study (NCT06300398), which demonstrated that IAMA-6 is safe and well tolerated in healthy volunteers, with a favorable pharmacokinetic profile.

Drug-Resistant Epilepsy Market Segmentation

DelveInsight's 'Drug-Resistant Epilepsy - Market Insights, Epidemiology, and Market Forecast - 2036' report provides a detailed outlook of the current and future Drug-Resistant Epilepsy market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Drug-Resistant Epilepsy Market Size by Countries

The Drug-Resistant Epilepsy market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2024, the United States held a significant share of the overall 7MM Drug-Resistant Epilepsy market, primarily attributed to the country's higher prevalence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Drug-Resistant Epilepsy Market Size by Therapies

Drug-Resistant Epilepsy Market Size by Therapies is categorized into current and emerging markets for the study period 2022-2036.

Drug-Resistant Epilepsy Drugs Uptake

This section focuses on the sales uptake of potential Drug-Resistant Epilepsy drugs that have recently been launched or are anticipated to be launched in the Drug-Resistant Epilepsy market between 2022 and 2036. It estimates the market penetration of Drug-Resistant Epilepsy drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the Drug-Resistant Epilepsy market. The emerging Drug-Resistant Epilepsy therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the Drug-Resistant Epilepsy market.

Drug-Resistant Epilepsy Market Access and Reimbursement

DelveInsight's 'Drug-Resistant Epilepsy Market Insights, Epidemiology, and Market Forecast - 2036' report provides a descriptive overview of the market access and reimbursement scenario of Drug-Resistant Epilepsy. This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

Drug-Resistant Epilepsy KOL Views

To keep up with current Drug-Resistant Epilepsy market trends and fill gaps in secondary findings, we interview KOLs and SMEs' working in the Drug-Resistant Epilepsy domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or Drug-Resistant Epilepsy market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the Drug-Resistant Epilepsy unmet needs.

Drug-Resistant Epilepsy: KOL Insights

DelveInsight's analysts connected with 20+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as, CDC, National Center for Chronic Disease Prevention and Health Promotion, US, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany; Hospices Civils De Lyon and University of Lyon, Lyon, France; Sapienza University, Rome, Italy; Hospital Universitario Virgen de la Arrixaca, Murcia, Spain; University of Sheffield, UK; Hiroshima University Hospital, Japan, among others.

"As per KOL from the US, Drug-Resistant Epilepsy poses significant challenges due to its complex nature, making it difficult to manage with conventional antiepileptic drugs. The condition often leads to frequent and severe seizures, adversely affecting patients' quality of life. Moreover, the lack of effective treatment options and the unpredictability of seizures contribute to the burden on patients and healthcare systems."

"As per KOL from the UK, treatment for Drug-Resistant Epilepsy typically involves a combination of multiple antiepileptic drugs, but success rates are often low. Surgical interventions, like resective surgery or neuromodulation techniques (e.g., vagus nerve stimulation), offer alternatives when medication fails. Emerging therapies, such as gene therapy and novel pharmacological agents, are under investigation to provide more effective and targeted treatment options."

"As per KOL from Japan, significant unmet needs remain in Drug-Resistant Epilepsy management, including the development of more effective and less invasive treatments. Improved diagnostic tools to identify Drug-Resistant Epilepsy earlier and more accurately are crucial. Additionally, there is a need for personalized medicine approaches to tailor treatments to individual patients, reducing the trial-and-error process currently prevalent in Drug-Resistant Epilepsy management."

Drug-Resistant Epilepsy Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the Drug-Resistant Epilepsy. Market, utilizing various competitive intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Major Drug-Resistant Epilepsy Companies

LivaNova, Neurona Therapeutics, IAMA Therapeutics, and others.

Drug-Resistant Epilepsy Clinical Trials Activities

The Drug-Resistant Epilepsy Therapeutics Market Report offers an analysis of therapeutic candidates in Phase II and III stages and examines Drug-Resistant Epilepsy Companies involved in developing targeted therapeutics for Drug-Resistant Epilepsy. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Drug-Resistant Epilepsy Pipeline Development Activities

The Drug-Resistant Epilepsy Therapeutics Market Report covers information on collaborations, acquisition and merger, licensing, patent details, and other information for emerging Drug-Resistant Epilepsy therapies.

Drug-Resistant Epilepsy Market Report Insights

• Drug-Resistant Epilepsy Patient Population
• Therapeutic Approaches
• Drug-Resistant Epilepsy Pipeline Analysis
• Drug-Resistant Epilepsy Market Size and Trends
• Drug-Resistant Epilepsy Market Opportunities
• Impact of Upcoming Therapies

Drug-Resistant Epilepsy Report Key Strengths

• 11-Year Drug-Resistant Epilepsy Market Forecast
• The 7MM Coverage
• Drug-Resistant Epilepsy Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Drug-Resistant Epilepsy Market
• Drug-Resistant Epilepsy Drugs Uptake

Drug-Resistant Epilepsy Market Report Assessment

• Current Drug-Resistant Epilepsy Treatment Practices
• Drug-Resistant Epilepsy Unmet Needs
• Drug-Resistant Epilepsy Product Profiles
• Drug-Resistant Epilepsy Market Attractiveness

Key Questions Answered in the Drug-Resistant Epilepsy Market Report

Drug-Resistant Epilepsy Market Insights

• How common is Drug-Resistant Epilepsy?
• What are the key findings of Drug-Resistant Epilepsy epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2022-2036)?
• What are the currently available treatments for Drug-Resistant Epilepsy?
• What are the disease risk, burden, and unmet needs of Drug-Resistant Epilepsy?
• At what CAGR is the Drug-Resistant Epilepsy market and its epidemiology is expected to grow in the 7MM during the forecast period (2026-2036)?
• How would the unmet needs impact the Drug-Resistant Epilepsy market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of Drug-Resistant Epilepsy in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2026-2036)?
• How many companies are currently developing therapies for the treatment of Drug-Resistant Epilepsy?

Reasons to Buy the Drug-Resistant Epilepsy Market

• The Drug-Resistant Epilepsy Therapeutics Market Report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Drug-Resistant Epilepsy Drugs Market.
• Insights on patient burden/disease: Drug-Resistant Epilepsy Prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan.
• Identification of strong upcoming players in the Drug-Resistant Epilepsy Drugs Market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the attribute analysis section to provide visibility around leading classes.
• Highlights of Drug-Resistant Epilepsy Drugs Market access and reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of KOL around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing Drug-Resistant Epilepsy Drugs Market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Executive Summary of Drug Resistant Epilepsy

3. Competitive Intelligence Analysis for Drug Resistant Epilepsy

4. Drug Resistant Epilepsy: Market Overview at a Glance

• 4.1. Drug Resistant Epilepsy Total Market Share (%) Distribution in 2022
• 4.2. Drug Resistant Epilepsy Total Market Share (%) Distribution in 2036

5. Drug Resistant Epilepsy: Disease Background and Overview

• 5.1. Introduction
• 5.2. Sign and Symptoms
• 5.3. Pathophysiology
• 5.4. Risk Factors
• 5.5. Diagnosis

6. Patient Journey

7. Drug Resistant Epilepsy Epidemiology and Patient Population

• 7.1. Epidemiology Key Findings
• 7.2. Assumptions and Rationale: 7MM
• 7.3. Epidemiology Scenario: 7MM
  • 7.3.1. Drug Resistant Epilepsy Epidemiology Scenario in the 7MM (2022-2036)
• 7.4. United States Epidemiology
  • 7.4.1. Drug Resistant Epilepsy Epidemiology Scenario in the United States (2022-2036)
• 7.5. EU-5 Country-wise Epidemiology
  • 7.5.1. Germany Epidemiology
    • 7.5.1.1. Drug Resistant Epilepsy Epidemiology Scenario in Germany (2022-2036)
  • 7.5.2. France Epidemiology
    • 7.5.2.1. Drug Resistant Epilepsy Epidemiology Scenario in France (2022-2036)
  • 7.5.3. Italy Epidemiology
    • 7.5.3.1. Drug Resistant Epilepsy Epidemiology Scenario in Italy (2022-2036)
  • 7.5.4. Spain Epidemiology
    • 7.5.4.1. Drug Resistant Epilepsy Epidemiology Scenario in Spain (2022-2036)
  • 7.5.5. United Kingdom Epidemiology
    • 7.5.5.1. Drug Resistant Epilepsy Epidemiology Scenario in the United Kingdom (2022-2036)
  • 7.5.6. Japan Epidemiology
    • 7.5.6.1. Drug Resistant Epilepsy Epidemiology Scenario in Japan (2022-2036)

8. Drug Resistant Epilepsy Treatment Algorithm, Current Treatment, and Medical Practices

• 8.1. Drug Resistant Epilepsy Treatment and Management
• 8.2. Drug Resistant Epilepsy Treatment Algorithm

9. Drug Resistant Epilepsy Unmet Needs

10. Key Endpoints of Drug Resistant Epilepsy Treatment

11. Drug Resistant Epilepsy Marketed Products

• 11.1. List of Drug Resistant Epilepsy Marketed Drugs in the 7MM
• 11.2. Drug Name: Company Name
  • 11.2.1. Product Description
  • 11.2.2. Regulatory Milestones
  • 11.2.3. Other Developmental Activities
  • 11.2.4. Pivotal Clinical Trials
  • 11.2.5. Summary of Pivotal Clinical Trial

12. Drug Resistant Epilepsy Emerging Therapies

• 12.1. Key Cross
• 12.2. Drug Name: Company Name
  • 12.2.1. Product Description
  • 12.2.2. Other Developmental Activities
  • 12.2.3. Clinical Development
  • 12.2.4. Safety and Efficacy
  • 12.2.5. Product Profile

13. Drug Resistant Epilepsy: Seven Major Market Analysis

• 13.1. Key Findings
• 13.2. Drug Resistant Epilepsy Market Size in 7MM
• 13.3. Drug Resistant Epilepsy Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

• 15.1. United States Drug Resistant Epilepsy Market Size
  • 15.1.1. Drug Resistant Epilepsy Total Market Size in the United States
  • 15.1.2. Drug Resistant Epilepsy Market Size by Therapies in the United States
• 15.2. EU-5 countries: Market Size and Outlook
• 15.3. Germany Drug Resistant Epilepsy Market Size
  • 15.3.1. Drug Resistant Epilepsy Total Market Size in Germany
  • 15.3.2. Drug Resistant Epilepsy Market Size by Therapies in Germany
• 15.4. France Drug Resistant Epilepsy Market Size
  • 15.4.1. Drug Resistant Epilepsy Total Market Size in France
  • 15.4.2. Drug Resistant Epilepsy Market Size by Therapies in France
• 15.5. Italy Drug Resistant Epilepsy Market Size
  • 15.5.1. Drug Resistant Epilepsy Total Market Size in Italy
  • 15.5.2. Drug Resistant Epilepsy Market Size by Therapies in Italy
• 15.6. Spain Drug Resistant Epilepsy Market Size
  • 15.6.1. Drug Resistant Epilepsy Total Market Size in Spain
  • 15.6.2. Drug Resistant Epilepsy Market Size by Therapies in Spain
• 15.7. United Kingdom Drug Resistant Epilepsy Market Size
  • 15.7.1. Drug Resistant Epilepsy Total Market Size in the United Kingdom
  • 15.7.2. Drug Resistant Epilepsy Market Size by Therapies in the United Kingdom
• 15.8. Japan Drug Resistant Epilepsy Market Outlook
  • 15.8.1. Japan Market Size
  • 15.8.2. Drug Resistant Epilepsy Total Market Size in Japan
  • 15.8.3. Drug Resistant Epilepsy Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Drug Resistant Epilepsy

17. KOL Views

18. Drug Resistant Epilepsy Market Drivers

19. Drug Resistant Epilepsy Market Barriers

20. Appendix

• 20.1. Bibliography
• 20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

The table of contents is not exhaustive; the final content may vary.